Dr John Riches
My research focus is investigating the interplay between BCR-signalling and metabolism in chronic lymphocytic leukaemia using a variety of proteomic and metabolic techniques.
I combine my laboratory and translational research programme with clinical practice with the Cancer Centre at Barts Health, with specific emphasis on the treatment of lymphoid malignancies including CLL, immunotherapy and bone marrow transplantation.
I qualified from Oxford University Medical School in 2003 and trained in haematology on the Imperial College training rotation.
I developed my research interest during my CRUK Clinical Research Fellowship with Professor Gribben at Barts Cancer Institute where I studied the defects underlying impaired T-cell immunity in chronic lymphocytic leukaemia (CLL) focusing on the impact of lenalidomide, being awarded a PhD in 2013. I stayed in this laboratory for a period of post-doctoral work investigating the expression and function of integrins on CLL cells. I was awarded the Hamblin prize by the UK CLL forum in 2015 for my work documenting the particular differences associated with the presence of trisomy 12.
In 2016, I joined the Centre for Haemato-Oncology in the Barts Cancer Institute as a Clinical Senior Lecturer funded initially as an Intermediate Clinical Fellow by the Wellcome Trust. I have been working at the Francis Crick Institute to investigate the interaction between signalling and metabolism in CLL cells.
2016 - Wellcome Trust Intermediate Clinical Fellowship: "Understanding the spatio-temporal dynamics of B-cell receptor signalling in chronic lymphocytic leukaemia" £863,503
2012 - Celgene Corporation: "The mechanism of action of lenalidomide on malignant and immune cells in chronic lymphocytic leukaemia" £103,791
2009 - Cancer Research UK Clinical research fellowship: "The defects underlying impaired T-cell immunity in chronic lymphocytic leukaemia: the impact of lenalidomide" £206,000
McClanahan F, Riches JC, Miller S, Day W, Kotsiou E, Neuberg D, Croce CM, Capasso M, Gribben JG. Mechanisms of PD-L1/PD-1 mediated CD8 T-cell defects in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model. Blood. 2015 Jul 9;126(2):212-21
Riches JC, O’Donovan CJ, Kingdon SJ, McClanahan F, Clear AJ, Neuberg DS, Werner L, Croce CM, Ramsay AG, Rassenti LZ, Kipps TJ, Gribben JG. Trisomy 12 Chronic Lymphocytic Leukemia cells exhibit up-regulation of integrin signaling that is modulated by NOTCH1 mutations. Blood 2014:123(26):4101-10.
Riches JC, Davies JK, McClanahan F, Iqbal S, Fatah R, Agrawal S, Ramsay AG, Gribben JG. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production Blood 2013: 121(9):1612-21
Ene-Obong A, Clea, AJ, Watt J, Wang J, Fatah R, Riches JC, Marshall JF, Chin-Aleong J, Chelala C, Gribben JG, Ramsay AG, Kocher HM. Activated Pancreatic Stellate Cells Sequester CD8+ T-Cells to Reduce Their Infiltration of the Juxtatumoral Compartment of Pancreatic Ductal Adenocarcinoma. Gastroenterology 2013 Nov;145(5): 1121-32
For additional publications, please click here
- 2014 – 2015: Intercollegiate Committee on Haematology
- 2014 – 2015: Trainees Advisory Committee Representative
- 2013 – 2015: UK CLL Forum Executive Committee
- March 2015: Winner of Hamblin Prize - best published work in the last 12 months by a UK CLL research group